Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 228

1.

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.

Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, James C, Bowen B, Rashid F.

Aliment Pharmacol Ther. 2003 Jan;17(2):201-10.

PMID:
12534404
[PubMed - indexed for MEDLINE]
Free Article
2.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
[PubMed - indexed for MEDLINE]
3.

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.

Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM.

Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1101-11.

PMID:
12362101
[PubMed - indexed for MEDLINE]
4.
5.

Etoricoxib.

Cochrane DJ, Jarvis B, Keating GM.

Drugs. 2002;62(18):2637-51; discussion 2652-3. Review.

PMID:
12466002
[PubMed - indexed for MEDLINE]
6.

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J.

Gastroenterology. 1999 Oct;117(4):776-83.

PMID:
10500058
[PubMed - indexed for MEDLINE]
7.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S; Etoricoxib Rheumatoid Arthritis Study Group.

J Rheumatol. 2002 Aug;29(8):1623-30.

PMID:
12180720
[PubMed - indexed for MEDLINE]
8.

Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.

Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM.

Aliment Pharmacol Ther. 2004 Sep 1;20(5):527-38.

PMID:
15339324
[PubMed - indexed for MEDLINE]
Free Article
9.

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.

Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA.

Am J Med. 2000 Aug 15;109(3):201-6.

PMID:
10974182
[PubMed - indexed for MEDLINE]
10.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.

Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E; Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.

Aliment Pharmacol Ther. 2001 Oct;15(10):1593-601.

PMID:
11563999
[PubMed - indexed for MEDLINE]
Free Article
11.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
[PubMed - indexed for MEDLINE]
12.

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.

Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE.

Aliment Pharmacol Ther. 1999 Jun;13(6):761-7.

PMID:
10383505
[PubMed - indexed for MEDLINE]
Free Article
13.

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.

Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.

Curr Med Res Opin. 2004 Dec;20(12):1899-908.

PMID:
15701208
[PubMed - indexed for MEDLINE]
14.

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.

Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE.

Aliment Pharmacol Ther. 2006 May 15;23(10):1489-98.

PMID:
16669964
[PubMed - indexed for MEDLINE]
Free Article
15.

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.

Curr Med Res Opin. 2005 May;21(5):715-22.

PMID:
15974563
[PubMed - indexed for MEDLINE]
16.

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee.

Lancet. 2006 Nov 18;368(9549):1771-81.

PMID:
17113426
[PubMed - indexed for MEDLINE]
17.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

PMID:
11136272
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.

Patrignani P, Capone ML, Tacconelli S.

Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review.

PMID:
12562317
[PubMed - indexed for MEDLINE]
19.

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.

Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS.

Clin Ther. 2004 Jan;26(1):70-83.

PMID:
14996519
[PubMed - indexed for MEDLINE]
20.

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.

Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, Geba GP; Etoricoxib Protocol 042 Study Group.

J Pain. 2003 Aug;4(6):307-15.

PMID:
14622687
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk